DarioHealth enters its September-quarter report with a peculiar mismatch. On the last call, management showcased record gross margins, a shrinking cost base, more than 180 signed accounts and a string of fresh wins. The stock has since lost nearly two-thirds of its value. The reason is simple: revenue went backward, and the company has repeatedly told investors that its contracted pipeline turns into recurring revenue in the second half of 2026, with most of it landing in 2027. This is the first report from inside that window, so it is the first real chance to see whether the conversion story is starting or slipping again.
The Street is not asking for much. Consensus calls for revenue of about $5.2 million, flat with the prior quarter and up roughly 3.9% from the $5.0 million reported a year ago. That is modest growth at best, and it implies analysts expect the sequential decline from $5.6 million to $5.2 million to stop rather than reverse sharply. The consensus loss of $0.68 per share would improve on the prior quarter's $0.85 loss and sharply on the $2.96 loss of a year earlier, though per-share comparisons should be read alongside the dollar net loss, which fell to $7.9 million last quarter from $13 million a year before. The company has not provided fresh quantitative guidance, so the call commentary is the main benchmark.
That commentary sets up several tests. Contracted plus late-stage annual recurring revenue has hovered around $12.4 million to $13.1 million for four straight calls, so evidence that this figure is growing, or better yet that a meaningful slice has moved into the revenue line, would validate the narrative. A return to sequential revenue growth, even a small one, would also help repair the streak management highlighted earlier in the year. Concrete progress on the newest catalysts matters too: enrollment at the fifth Fortune 50 employer, activity from the Amwell channel's Arizona insurer win, the hypertension expansion at a top-five insurer that management sized at roughly three times the original opportunity, and early traction for the GLP-1 program. Dario Women and Dario Sleep are slated to contribute revenue in the fourth quarter, so any update confirming that timing would be welcome.
On the other side of the ledger, margins and costs need to hold. Gross margin jumped to an all-time high of 62% from 57% the prior quarter, and operating expenses fell 21% year over year. Sustaining something near those levels would show that the profitability improvement is structural rather than a one-quarter mix benefit. Investors should also listen for whether the company restores some of the disclosures it dropped last quarter, including the total pipeline figure and covered-lives reach, and whether it reattaches a timeline to cash-flow breakeven, which has softened into a vaguer path. An update on President and Chief Commercial Officer Steven Nelson, who was on medical leave, and the large channel partner said to be in final contracting would round out the picture.
Sentiment has moved from deeply bearish heading into the last report to roughly neutral now, which suggests some of the pessimism has been wrung out alongside the share price. At $2.73, the stock sits just above its post-earnings low of $2.69 and far beneath its 200-day moving average near $7.58, a sign the market has priced in considerable doubt. That lowers the bar, but it does not remove it.
Ultimately, this quarter hinges on one question: can DarioHealth show that its expanding account base and multi-condition contracts are beginning to convert into reported revenue on the schedule management laid out? Another flat-to-down top line paired with another deferral would undercut the compounding story, regardless of margin gains. Visible conversion, even early, would give the improving cost and margin profile something to compound.